IGHG3 and neoplasm: Clearly, the impact of B-cells in cancer immunology is not black and white, and we cannot simply distinguish “positive” IgG1/IgG3 isotypes that initiate tumor-specific ADCC and immune responses from “negative” IgA/IgG4 isotypes as a signature of or precursor to immunosuppression.